Main Article Content
Background. Dipeptidyl peptidase4 inhibitors, having incretin activity, influence the main pathogenetic mechanisms of type 2 diabetes mellitus (DM). Vildagliptin is an innovative dipeptidyl peptidase4 inhibitor with unique pharmacokinetic characteristics, the efficacy and safety of which have been studied in placebocontrolled studies. The purpose: to study the pharmacotherapeutic efficacy, safety and tolerability of Gliptar produced by PJSC “Kievmedpreparat” (Ukraine) in the treatment of patients with type 2 DM. Materials and methods. The study included 49 patients with type 2 DM. They received metformin monotherapy at a dose of at least 1,000 mg daily for at least the last six months. Duration of type 2 DM averaged 6.2 ± 1.8 years. The patients formed two groups for followup. The first group consisted of 29 patients who were still taking metformin doses up to 2,000 mg/day and additionally received Gliptar (vildagliptin) at a dose of 50 mg twice daily. Patients in the second group (n = 20) continued to receive metformin twice daily at a dose of 2,000 mg/day. Results. After 12 weeks in patients of the first group on the background of metformin therapy combined with vildagliptin, the level of HbA1c decreased significantly to 6.42 ± 0.21 %, fasting glycemia — to 6.14 ± 0.22 mmol/l, postprandial glycemia — to 8.63 ± 0.23 mmol/l. On the background of combined treatment, patients with type 2 DM had a decrease in body weight by 1.18 kg, as well as a tendency to decrease in body mass index from 31.49 ± 1.08 kg/m2 to 29.98 ± 0.76 kg/m2. After treatment, the level of immunoreactive insulin in the first group was 14.08 ± 1.83 µU/ml (baseline 21.11 ± 2.03 µU/ml), HOMAIR — 3.14 ± 0.21 (baseline 6.28 ± 1.42). A significant decrease in carbohydrate metabolism and insulin resistance can be assessed as a positive trend in combination therapy. Conclusions. Given the benefits of dual therapy in the treatment of patients with type 2 DM, according to conventional stepbystep therapy, in the second stage it is advisable to prescribe vildagliptin to patients who receive metformin and who have not reached the target glycemic control. Combination therapy of vildagliptin and metformin provides a comprehensive effect on cardiovascular risk factors in the form of preventing hyperinsulinemia and reducing insulin resistance.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
Mathieu C, Kozlovski P, Paldánius PM, et al. Clinical Safety and Tolerability of Vildagliptin - Insights from Randomised Trials, Observational Studies and Post-marketing Surveillance. Eur Endocrinol. 2017 Aug;13(2):68-72. doi: 10.17925/EE.2017.13.02.68.
Hayashi T, Murayama H, Shinfuku Y, Taniguchi T, Tsumiyama I, Oyama N. Safety and efficacy of vildagliptin: 52-week post-marketing surveillance of Japanese patients with type 2 diabetes in combination with other oral antidiabetics and insulin. Expert Opin Pharmacother. 2019 Nov 5:1-10. doi: 10.1080/14656566.2019.1685500.
Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev. 2017 May 10;5:CD012204. doi: 10.1002/14651858.CD012204.pub2.
Yavropoulou MP, Pikilidou M, Kotsa K, Michopoulos A, Papakonstantinou E, Yovos JG. Efficacy and tolerability of vildagliptin as first line treatment in patients with diabetes type 2 in an outpatient setting. J Diabetes Metab Disord. 2015 Aug 22;14:68. doi: 10.1186/s40200-015-0194-6.
Rizzo MR, Barbieri M, Marfella R, Paolisso G. Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes: Role of dipeptidyl peptidase-IV inhibition. Diabetes Care. 2012 Oct;35(10):2076-82. doi: 10.2337/dc12-0199.
He YL, Yamaguchi M, Ito H, Terao S, Sekiguchi K. Pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with type 2 diabetes. Int J Clin Pharmacol Ther. 2010 Sep;48(9):582-95. doi: 10.5414/cpp48582.
El-Ouaghlidi A, Rehring E, Holst JJ, et al. The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion. J Clin Endocrinol Metab. 2007 Nov;92(11):4165-71. doi: 10.1210/jc.2006-1932.
Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of Vildagliptin on Glucose Control Over 24 Weeks in Patients with Type 2 Diabetes Inadequately Controlled with Metformin. Diabetes Care. 2007 Apr;30(4):890-5. doi: 10.2337/dc06-1732.
McInnes G, Evans M, Del Prato S, et al. Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients. Diabetes Obes Metab. 2015 Nov;17(11):1085-92. doi: 10.1111/dom.12548.
Schweizer A, Dejager S, Foley JE, Kothny W. Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies. Vasc Health Risk Manag. 2011;7:49-57. doi: 10.2147/VHRM.S16925.
Strain WD, Lukashevich V, Kothny W, Hoellinger MJ, Paldánius PM. Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study. Lancet. 2013 Aug 3;382(9890):409-416. doi: 10.1016/S0140-6736(13)60995-2.
Williams R, de Vries F, Kothny W, et al. Cardiovascular safety of vildagliptin in patients with type 2 diabetes: a European multi-database, non-interventional post-authorization safety study. Diabetes Obes Metab. 2017 Oct;19(10):1473-1478. doi: 10.1111/dom.12951.
Makrilakis K. The Role of DPP-4 Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect. Int J Environ Res Public Health. 2019 Jul 30;16(15). pii: E2720. doi: 10.3390/ijerph16152720.
Douros A, Rouette J, Yin H, Yu OHY, Filion KB, Azoulay L. Dipeptidyl Peptidase-4 Inhibitors and the Risk of Bullous Pemphigoid Among Patients With Type 2 Diabetes. Diabetes Care. 2019 Aug;42(8):1496-1503. doi: 10.2337/dc19-0409.